KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Pharmaceutical Sciences / 2018 / Cilt: 15 - Sayı: 3

The Effect of Sumatriptan in Ischemic Conditions in the Rat Heart

Sumatriptanın Sıçan Kalbinde İskemik Koşullardaki Etkisi

Hande Özge ALTUNKAYNAK ÇAMCA
Müge TECDER ÜNAL
MERAL TUNCER
Sayfa
328–332
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Although SUM diminishes IPC-induced protection againstVT, the preventive effect of SUM against VF may be predictive for cardioprotection in ischemic conditions.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: The aim of this study was to investigate the effect of SUM on IR-induced injury in rat heart and its effect on IPC-induced protection.Materials and Methods: The rats were randomly divided into four groups: IR, SUM-IR, IPC, and SUM-IPC.
📊
Temel Bulgular & Veri:The mean arterial blood pressure andheart rate were recorded to calculate PRP.
💡
Sonuç & Katkı:Although SUM diminishes IPC-induced protection againstVT, the preventive effect of SUM against VF may be predictive for cardioprotection in ischemic conditions.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: The aim of this study was to investigate the effect of SUM on IR-induced injury in rat heart and its effect on IPC-induced protection.Materials and Methods: The rats were randomly divided into four groups: IR, SUM-IR, IPC, and SUM-IPC. The mean arterial blood pressure andheart rate were recorded to calculate PRP. Standard limb lead 2 ECG were recorded to evaluate arrhythmia parameters.Results: The PRP values in the SUM-IPC group were significantly lower than in the SUM-IR group at the beginning of reperfusion (p<0.05). Theincidence of VT in the IPC, SUM-IR, and SUM-IPC groups was significantly lower than in the IR group (p<0.05). VF was only observed in the IRgroup.Conclusion: SUM protects the heart against IR injury but is not as protective as IPC alone. Although SUM diminishes IPC-induced protection againstVT, the preventive effect of SUM against VF may be predictive for cardioprotection in ischemic conditions.

Abstract

Amaç: Bu çalışmanın amacı, SUM’un, IR’nin sıçanlarda neden olduğu kardiyak hasar ve IPC’nin oluşturduğu koruyuculuk üzerine etkisini incelemektir. Gereç ve Yöntemler: Sıçanlar rastgele olarak; IR, SUM-IR, IPC ve SUM-IPC gruplarına bölündü. Ortalama arteriyel kan basıncı ve kalp atım hızı, basınç hız ürününü (PRP) hesaplamak için kaydedildi. Aritmi parametrelerini değerlendirmek için standart EKG’ler kaydedildi. Bulgular: SUM-IPC grubundaki PRP değerleri, SUM-IR grubundakilerden reperfüzyon başlangıcında anlamlı olarak daha düşüktü (p<0.05). IPC, SUM-IR ve SUM-IPC gruplarındaki VT insidansı, IR grubundakinden anlamlı olarak daha düşüktü (p<0.05). VF sadece IR grubunda gözlendi. Sonuç: IPC’nin koruyucu etkisi kadar olmasa da, sumatriptan’ın kalbi IR hasarına karşı koruduğu gözlenmiştir. SUM VT’ye karşı IPC’nin oluşturduğu koruyuculuğu kısmen azaltsa da, VF’ye karşı önleyici etkisi iskemik koşullarda kalp için koruyucu olabilir.

🔖

Bu Makaleye Atıf Yap

ÇAMCA, H. Ö. A., ÜNAL, M. T., TUNCER, M. (2018). The Effect of Sumatriptan in Ischemic Conditions in the Rat Heart. Turkish Journal of Pharmaceutical Sciences, Cilt: 15 - Sayı: 3, 328–332. https://ajindex.com/articles/404134

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Ramage AG, Villalón CM. 5-hydroxytryptamine and cardiovascular regulation. Trends Pharmacol Sci. 2008;29:472-481. Villalón CM, De Vries P, Saxena PR. Serotonin receptors as cardiovascular targets. Drug Discovery Today. 1997;2:294-300. Weiss O. Ueber die Wirkungen von Blutserum-Injectionen ins Blut. Archiv für die Gesamte Physiologie des Menschen und der Thiere. 1896;65:215-230.
  2. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev. 1994;46:157-203.
  3. Duquesnoy C, Mamet JP, Sumner D, Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci. 1998;6:99-104. Villalón CM, Centurión D. Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors/ mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol. 2007;376:45-63.
  4. Mueller L, Gallagher RM, Ciervo CA. Vasospasm-induced myocardial infarction with sumatriptan. Headache. 1996;36:329-331.
  5. Laine K, Raasakka T, Mäntynen J, Saukko P. Fatal cardiac arrhythmia after oral sumatriptan. Headache. 1999;39:511-512.
  6. Lynch JJ Jr, Stump GL, Kane SA, Regan CP. The prototype serotonin 5-HT 1B/1D agonist sumatriptan increases the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis. J Cardiovasc Pharmacol. 2009;53:474-479.
  7. Kemp BK, Cocks TM. Effects of U46619 on contractions to 5-HT, sumatriptan and methysergide in canine coronary artery and saphenous vein in vitro. Br J Pharmacol. 1995;116:2183-2190.
  8. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev. 2007;59:418-458.
  9. Krzeminski TF, Mitrega K, Porc M, Zorniak M, Ryszka F, Ostrowska Z, Kos-Kudła B. Differential action of two prolactin isoforms on ischemia and re-perfusion-induced arrhythmias in rats in vivo. J Endocrinol Invest. 2011;34:206-215.
  10. Baller D, Bretschneider HJ, Hellige G. A critical look at currently used indirect indices of myocardial oxygen consumption. Bas Res Cardiol. 1981;76:163-181.
  11. Fawaz G, Tutunji B. Ouabain-induced ventricular tachycardia and its effect on the performance and metabolism of the dog heart. Br J Pharmacol Chemother. 1959;14:355-357.
  12. Spokes RA, Middlefell VC. Simult